Biovica announces that the company's quality system is updated in accordance with ISO 13485:2016.
Uppsala, Sweden, February 4, 2019. Biovica, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome, announced today that the company has certified their Quality System according to the ISO13485:2016 standard for the development, manufacturing and sale of DiviTum® at the yearly surveillance audit with Biovica’s notified body.Biovica has been ISO certified since 2010. The update means that Biovica continues to fulfil the regulatory requirements for the development, manufacturing and sale of the company’